| dc.contributor.author | Aykan, N. F. | |
| dc.contributor.author | Idelevich, E. | |
| dc.date.accessioned | 2021-03-03T20:11:51Z | |
| dc.date.available | 2021-03-03T20:11:51Z | |
| dc.date.issued | 2008 | |
| dc.identifier.citation | Aykan N. F. , Idelevich E., "The role of UFT in advanced gastric cancer", ANNALS OF ONCOLOGY, cilt.19, sa.6, ss.1045-1052, 2008 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.other | av_5899a070-68a8-4aaa-815b-965d1d08b50c | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/62384 | |
| dc.identifier.uri | https://doi.org/10.1093/annonc/mdn024 | |
| dc.description.abstract | Background: Advanced gastric cancer has a poor prognosis, with a relative 5-year survival rate of 7%-27%. Chemotherapy, which improves overall survival (OS) and quality of life, is the main treatment option. Although numerous regimens have been investigated, there is no standard treatment. Combination chemotherapy, however, is associated with a significant survival benefit compared with monotherapy and i.v. 5-fluorouracil (5-FU) is one of the most widely used agents. UFT (tegafur-uracil) has similar efficacy to continuous infusion 5-FU with improved tolerability and is more convenient for patients. | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.title | The role of UFT in advanced gastric cancer | |
| dc.type | Makale | |
| dc.relation.journal | ANNALS OF ONCOLOGY | |
| dc.contributor.department | The Hebrew University Of Jerusalem , , | |
| dc.identifier.volume | 19 | |
| dc.identifier.issue | 6 | |
| dc.identifier.startpage | 1045 | |
| dc.identifier.endpage | 1052 | |
| dc.contributor.firstauthorID | 188201 | |
